Biological Products, (No Diagnostic Substances) · POMPANO BEACH, FL, United States
$3.54
-4.07% (-$0.15)2026-08-21
Smart-Money SignalNeutral · 50/100— Insider open-market flow is flat over 90 days
Revenue$14.0M
Net Income-$17.8M
EPS$-1.04
Gross Margin61.3%
Market Cap$63.2M
Price Performance
Historical data including institutional events
Company Profile
J
Jason Matuszewski
CEO & Executive Director
BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States.
It offers Vendaje, a human connective tissue matrix compromised of amniotic tissue intended for wound covering; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje OPTIC, a structural tissue allograft used as a protective covering during the repair of ocular surfaces; American Amnion AC, a human connective tissue matrix for homologous use; and American Amnion, a human connective tissue matrix for homologous use.
The company was formerly known as Caribbean International Holdings Inc. and changed its name to BioStem Technologies, Inc. in August 2014.
BioStem Technologies, Inc. was incorporated in 2006 and is based in Fort Lauderdale, Florida.